Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403690 | 0.84 | DUT (0.43) | DUT | |
| SCHEMBL8545478 | 0.81 | DUT (0.36) | DUT | |
| SCHEMBL1315036 | 0.80 | IDO1 (0.46) | BACE1 | |
| SCHEMBL28326219 | 0.79 | — | — | |
| SCHEMBL5342752 | 0.79 | BACE1 (0.32) | BACE1 | |
| SCHEMBL1008605 | 0.79 | — | — | |
| SCHEMBL15489965 | 0.78 | TDP1 (0.37) | BACE1DUT | |
| SCHEMBL906834 | 0.78 | IDO1 (0.48) | BACE1 | |
| SCHEMBL12855670 | 0.78 | AGXT (0.52) | — | |
| SCHEMBL581041 | 0.78 | LOXL2 (0.37) | BACE1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | claimed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | claimed |
| CN-118201644-A | Ligand compounds comprising chelating groups as bridging groups | 慕尼黑工业大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-113677375-A | Fluorinated silicon receptor substituted radiopharmaceuticals and precursors thereof | 慕尼黑工业大学 | 2021-11-19 | — | — | CN | disclosed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| CN-1423645-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2003-06-11 | — | — | CN | disclosed |
| US-6197905-B1 | VINYL ETHER CHAIN TRANSFER AGENT TERMINATES THE GROWTH OF THE POLYMER CHAIN BY ADDITION TO THE PROPAGATING POLYMER RADICAL FOLLOWED BY EXPULSION OF A RADICAL WHICH THEN INITIATES ANOTHER POLYMER CHAIN | COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESARCH ORGANIZATION (AU) | 2001-03-06 | — | — | US | disclosed |
| US-5932675-A | Free-radical chain transfer polymerization process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-08-03 | — | — | US | disclosed |
| US-5874511-A | CHAIN TRANSFER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0333758-B1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS | COMMW SCIENT IND RES ORG (AU) | 1995-11-02 | — | — | EP | disclosed |
| US-5385996-A | Control of molecular weight and end-group functionality of polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1995-01-31 | — | — | US | disclosed |
| EP-0333758-A4 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS. | COMMW SCIENT IND RES ORG (AU) | 1990-05-14 | — | — | EP | disclosed |
| EP-0333758-A1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS. | COMMW SCIENT IND RES ORG (AU) | 1989-09-27 | — | — | EP | disclosed |
| WO-1988004304-A1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | BACE1 4399/4885DUT 278/4885 |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | APC, BRCA1, VHL | BACE1 4120/4885DUT 932/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | BACE1 4399/4885DUT 278/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | BACE1 4399/4885DUT 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.